Hsbc Holdings PLC Reduces Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Hsbc Holdings PLC decreased its stake in Silence Therapeutics plc (NASDAQ:SLN) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 172,834 shares of the company’s stock after selling 5,000 shares during the period. Hsbc Holdings PLC’s holdings in Silence Therapeutics were worth $1,193,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Marshall Wace LLP boosted its stake in Silence Therapeutics by 190.3% in the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock valued at $3,364,000 after acquiring an additional 320,472 shares in the last quarter. Trexquant Investment LP purchased a new position in Silence Therapeutics during the 4th quarter worth approximately $438,000. Walleye Capital LLC acquired a new position in Silence Therapeutics during the fourth quarter worth approximately $250,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Silence Therapeutics in the fourth quarter valued at approximately $134,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $120,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SLN shares. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. The Goldman Sachs Group decreased their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research note on Tuesday, March 4th. BMO Capital Markets dropped their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price objective on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Silence Therapeutics Trading Down 2.0 %

NASDAQ SLN opened at $3.93 on Friday. The stock has a market capitalization of $117.62 million, a price-to-earnings ratio of -2.50 and a beta of 1.25. The business’s 50 day moving average is $3.47 and its two-hundred day moving average is $7.07. Silence Therapeutics plc has a 12-month low of $1.97 and a 12-month high of $24.38.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.